Compare Medtronic PLC (MDT) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Xylem, Inc. — how do they compare? Medtronic PLC trades at $90.64 (market cap $116.07B), while Xylem, Inc. trades at $121.75 (market cap $28.76B). The key difference: Medtronic PLC is far larger — about 4× Xylem, Inc.'s market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| MDT | XYL | |
|---|---|---|
Market Cap | $116.07B | $28.76B |
Sector | Health | Industrials |
52-Week High | $105.35 | $152.95 |
52-Week Low | $73.75 | $106.34 |
Enterprise Value | $134.82B | $30.54B |
Dividend Yield | 3.18% | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
XYL trades at $121.59, up 0.33% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $9.04B in 2025, with net income margin expanding to 10.59%. Recent acquisitions like Cornell Pump and Roper Pump aim to strengthen its industrial water technology presence, while AI-driven demand for water-treatment equipment supports growth.
The outlook is positive, with a consensus price target of $150.43 implying 24% upside, backed by margin expansion and strategic acquisitions. Risks include execution of integration and potential revenue delays from electric metering projects, as noted in Q2 2026 results. Analyst sentiment is mixed but leans bullish, with 47.5% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
